Navigation Links
Innophos Holdings, Inc. Schedules Call to Discuss Fourth Quarter And Full Year 2012 Results
Date:2/6/2013

CRANBURY, N.J., Feb. 6, 2013 /PRNewswire/ -- Innophos Holdings, Inc. (NASDAQ: IPHS), a leading international producer of performance-critical and nutritional specialty ingredients, today announced that it will host a live conference call on Friday, February 15, 2013 at 10:00 am ET to discuss its fourth quarter and full year 2012 results.

The press release detailing fourth quarter and full year results will be issued on Thursday, February 14, 2013 after market close.

The conference call can be accessed by dialing 888-206-4065(U.S.) or 630-827-5974 (international) and entering passcode 34232459.  A replay will be available between 1:00 pm ET on February 15 and 1:00 pm ET on February 28, 2013.  The replay is accessible by dialing 888-843-7419 (U.S.) or 630-652-3042 (international) and entering passcode 6861213#.

If you would like to pre-register for the conference call use the following link:
https://www.yourconferencecenter.com/confcenter/PinCode/Pin_Code.aspx?100374&o=UhCYKEQPKSYgHgPre-registering is highly recommended, as it will provide you immediate entry into the call and will facilitate the timely start of the conference. You will receive a code that allows you to enter the call directly.  Pre-registration only takes a few moments, and you may do so at any time, including up to and after call start time. To pre-register, please click the link above. Alternately, if you would rather be placed into the call by an operator, please call at least 15 minutes prior to call start time.

Alternately, the webcast of the conference call can be accessed live and as a replay at Innophos' web site www.innophos.com in the Investor Relations Events section.

About Innophos Holdings, Inc.
Innophos is a leading international producer of performance-critical and nutritional specialty ingredients, with applications in food, beverage, dietary supplements, pharmaceutical, oral care and industrial end markets.  Innophos combines more than a century of experience in specialty phosphate manufacturing with a growing capability in a broad range of other specialty ingredients to supply a product range produced to stringent regulatory manufacturing standards and the quality demanded by customers worldwide.  Innophos is continually developing new and innovative specialty ingredients addressing specific customer applications and supports these high-value products with industry-leading technical service.  Headquartered in Cranbury, New Jersey, Innophos has manufacturing operations in Nashville, TN; Chicago Heights, IL; Chicago (Waterway), IL; Geismar, LA; Ogden, UT; North Salt Lake, UT; Paterson, NJ; Green Pond, SC; Port Maitland, ON (Canada); and Coatzacoalcos, Veracruz and San Jose de Iturbide (Mission Hills), Guanajuato (Mexico). For more information please visit www.innophos.com. 'IPHS-G'

Innophos Investor Relations 

FTI Consulting, Inc.(609) 366-1299

Alexandra Tramontinvestor.relations@innophos.com  

Matt Steinberg(212) 850-5600


'/>"/>
SOURCE Innophos Holdings, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Innophos To Present At 2012 KeyBanc Capital Markets Basic Materials & Packaging Conference
2. Organovo Holdings, Inc. announces redemption of 2.9 million outstanding warrants
3. Free Research Report on Laboratory Corp. of America Holdings, Sony Corp., Cyberonics, Inc., Olin Corp. and Deluxe Corp.
4. Market Boosted by Strong Tech Earnings: Bank of America Corp., MAP Pharmaceuticals Inc., Swingplane Ventures Inc., World Moto, Inc., Organovo Holdings, Inc.
5. Zacks Sell List Highlights: J.C. Penney, Spirit AeroSystems Holdings, The New York Times and Jazz Pharmaceuticals
6. China Pharma Holdings, Inc. Reports Third Quarter 2012 Financial Results
7. Zimmer Holdings, Inc. Reports Third Quarter 2012 Financial Results
8. China Pharma Holdings, Inc. Reports Second Quarter 2012 Financial Results
9. RxAlly Member Pharmacies Invited To Become The Preferred Network For Smart Insurance Company Holdings, Inc.
10. InfuSystem Holdings, Inc. Reports $14.1 Million of Revenues for the Second Quarter of 2012; Announces Annualized Cost Savings in Excess of $1 million
11. China Pharma Holdings, Inc. to Report Second Quarter of Fiscal Year 2012 Financial Results on August 15, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased ... Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network ... experience in dermatology, skin cancer , and more. She graduated from the University ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and ... the rise, say researchers presenting their work at the American Orthopaedic Society ... combination of evaluating the patterns of change in concussion symptom presentation, diagnostic tools ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
Breaking Medicine News(10 mins):